Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART

V. Tozzi, P. Balestra, R. Murri, S. Galgani, R. Bellagamba, P. Narciso, A. Antinori, M. Giulianelli, G. Tosi, M. Fantoni, A. Sampaolesi, P. Noto, G. Ippolito, A. W. Wu

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The objective of the study was to determine the association of neurocognitive impairment with health-related quality of life (HRQoL) in patients receiving highly active antiretroviral therapy (HAART). Seventy subjects were cross-sectionally analysed with a standardized neuropsychological test battery and a questionnaire including an Italian translation of the MOS-HIV Health Survey. The presence of neurocognitive impairment was significantly associated with lower HRQoL scores: pain (P = 0.03), physical functioning (P = 0.01), role functioning (P = 0.01), social functioning (P = 0.029), mental health (P = 0.001), energy (P = 0.036), health distress (P = 0.002), cognitive functioning (P = 0.05), current health perception (P <0.001), physical health summary score (PHS) (P = 0.005), mental health summary score (MHS) (P = 0.002). Years of education (odds ratio [OR] 0.79; 95% confidence interval [CI] 0.65-0.96), PHS (OR 0.71; 95% CI 0.54-0.95) and MHS (OR 0.67; 95% CI 0.51-0.88) were also associated with cognitive impairment. Neurocognitive impairment in patients receiving HAART was associated with reduced HRQoL. Identifying cognitive impairment may provide motivation for additional treatment to help patients to compensate for deficits in functioning.

Original languageEnglish
Pages (from-to)254-259
Number of pages6
JournalInternational Journal of STD and AIDS
Volume15
Issue number4
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Highly Active Antiretroviral Therapy
Quality of Life
HIV
Mental Health
Odds Ratio
Health
Confidence Intervals
Neuropsychological Tests
Health Surveys
Motivation
Education
Pain
Cognitive Dysfunction
Therapeutics

Keywords

  • Highly active antiretroviral therapy
  • HIV
  • Neurocognitive impairment
  • Quality of life

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Cite this

Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. / Tozzi, V.; Balestra, P.; Murri, R.; Galgani, S.; Bellagamba, R.; Narciso, P.; Antinori, A.; Giulianelli, M.; Tosi, G.; Fantoni, M.; Sampaolesi, A.; Noto, P.; Ippolito, G.; Wu, A. W.

In: International Journal of STD and AIDS, Vol. 15, No. 4, 04.2004, p. 254-259.

Research output: Contribution to journalArticle

Tozzi, V. ; Balestra, P. ; Murri, R. ; Galgani, S. ; Bellagamba, R. ; Narciso, P. ; Antinori, A. ; Giulianelli, M. ; Tosi, G. ; Fantoni, M. ; Sampaolesi, A. ; Noto, P. ; Ippolito, G. ; Wu, A. W. / Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. In: International Journal of STD and AIDS. 2004 ; Vol. 15, No. 4. pp. 254-259.
@article{aabd3263010e45bfb5a8e5cf29eb7a5e,
title = "Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART",
abstract = "The objective of the study was to determine the association of neurocognitive impairment with health-related quality of life (HRQoL) in patients receiving highly active antiretroviral therapy (HAART). Seventy subjects were cross-sectionally analysed with a standardized neuropsychological test battery and a questionnaire including an Italian translation of the MOS-HIV Health Survey. The presence of neurocognitive impairment was significantly associated with lower HRQoL scores: pain (P = 0.03), physical functioning (P = 0.01), role functioning (P = 0.01), social functioning (P = 0.029), mental health (P = 0.001), energy (P = 0.036), health distress (P = 0.002), cognitive functioning (P = 0.05), current health perception (P <0.001), physical health summary score (PHS) (P = 0.005), mental health summary score (MHS) (P = 0.002). Years of education (odds ratio [OR] 0.79; 95{\%} confidence interval [CI] 0.65-0.96), PHS (OR 0.71; 95{\%} CI 0.54-0.95) and MHS (OR 0.67; 95{\%} CI 0.51-0.88) were also associated with cognitive impairment. Neurocognitive impairment in patients receiving HAART was associated with reduced HRQoL. Identifying cognitive impairment may provide motivation for additional treatment to help patients to compensate for deficits in functioning.",
keywords = "Highly active antiretroviral therapy, HIV, Neurocognitive impairment, Quality of life",
author = "V. Tozzi and P. Balestra and R. Murri and S. Galgani and R. Bellagamba and P. Narciso and A. Antinori and M. Giulianelli and G. Tosi and M. Fantoni and A. Sampaolesi and P. Noto and G. Ippolito and Wu, {A. W.}",
year = "2004",
month = "4",
doi = "10.1258/095646204773557794",
language = "English",
volume = "15",
pages = "254--259",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART

AU - Tozzi, V.

AU - Balestra, P.

AU - Murri, R.

AU - Galgani, S.

AU - Bellagamba, R.

AU - Narciso, P.

AU - Antinori, A.

AU - Giulianelli, M.

AU - Tosi, G.

AU - Fantoni, M.

AU - Sampaolesi, A.

AU - Noto, P.

AU - Ippolito, G.

AU - Wu, A. W.

PY - 2004/4

Y1 - 2004/4

N2 - The objective of the study was to determine the association of neurocognitive impairment with health-related quality of life (HRQoL) in patients receiving highly active antiretroviral therapy (HAART). Seventy subjects were cross-sectionally analysed with a standardized neuropsychological test battery and a questionnaire including an Italian translation of the MOS-HIV Health Survey. The presence of neurocognitive impairment was significantly associated with lower HRQoL scores: pain (P = 0.03), physical functioning (P = 0.01), role functioning (P = 0.01), social functioning (P = 0.029), mental health (P = 0.001), energy (P = 0.036), health distress (P = 0.002), cognitive functioning (P = 0.05), current health perception (P <0.001), physical health summary score (PHS) (P = 0.005), mental health summary score (MHS) (P = 0.002). Years of education (odds ratio [OR] 0.79; 95% confidence interval [CI] 0.65-0.96), PHS (OR 0.71; 95% CI 0.54-0.95) and MHS (OR 0.67; 95% CI 0.51-0.88) were also associated with cognitive impairment. Neurocognitive impairment in patients receiving HAART was associated with reduced HRQoL. Identifying cognitive impairment may provide motivation for additional treatment to help patients to compensate for deficits in functioning.

AB - The objective of the study was to determine the association of neurocognitive impairment with health-related quality of life (HRQoL) in patients receiving highly active antiretroviral therapy (HAART). Seventy subjects were cross-sectionally analysed with a standardized neuropsychological test battery and a questionnaire including an Italian translation of the MOS-HIV Health Survey. The presence of neurocognitive impairment was significantly associated with lower HRQoL scores: pain (P = 0.03), physical functioning (P = 0.01), role functioning (P = 0.01), social functioning (P = 0.029), mental health (P = 0.001), energy (P = 0.036), health distress (P = 0.002), cognitive functioning (P = 0.05), current health perception (P <0.001), physical health summary score (PHS) (P = 0.005), mental health summary score (MHS) (P = 0.002). Years of education (odds ratio [OR] 0.79; 95% confidence interval [CI] 0.65-0.96), PHS (OR 0.71; 95% CI 0.54-0.95) and MHS (OR 0.67; 95% CI 0.51-0.88) were also associated with cognitive impairment. Neurocognitive impairment in patients receiving HAART was associated with reduced HRQoL. Identifying cognitive impairment may provide motivation for additional treatment to help patients to compensate for deficits in functioning.

KW - Highly active antiretroviral therapy

KW - HIV

KW - Neurocognitive impairment

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=2342595777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342595777&partnerID=8YFLogxK

U2 - 10.1258/095646204773557794

DO - 10.1258/095646204773557794

M3 - Article

VL - 15

SP - 254

EP - 259

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 4

ER -